PriceTargets.com logo

NASDAQ:OMCL - Omnicell Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $162.40
  • Forecasted Upside: 48.75 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$109.18 As of 08/11/2022 01:00 AM ET
▲ +1.85 (1.72%)

This chart shows the closing price for OMCL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Omnicell Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OMCL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OMCL

Analyst Price Target is $162.40
▲ +48.75% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Omnicell in the last 3 months. The average price target is $162.40, with a high forecast of $205.00 and a low forecast of $124.00. The average price target represents a 48.75% upside from the last price of $109.18.

This chart shows the closing price for OMCL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Omnicell. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/18/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/19/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/17/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/15/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/13/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/14/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/13/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/12/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/8/2022Piper SandlerLower Price TargetOverweight$162.00 ➝ $150.00Low
7/27/2022BTIG ResearchLower Price TargetBuy$190.00 ➝ $175.00Low
7/15/2022SVB LeerinkInitiated CoverageMarket Perform ➝ Market Perform$124.00Low
5/3/2022Wells Fargo & CompanyLower Price TargetOverweight$188.00 ➝ $158.00Low
5/2/2022Piper SandlerLower Price Target$181.00 ➝ $162.00Low
2/16/2022Wells Fargo & CompanyLower Price TargetOverweight$203.00 ➝ $188.00High
12/6/2021Wells Fargo & CompanyInitiated CoverageOverweight$203.00High
12/1/2021BTIG ResearchBoost Price TargetPositive ➝ Buy$210.00 ➝ $220.00Low
11/3/2021Craig HallumBoost Price TargetBuy$170.00 ➝ $205.00Low
11/3/2021Piper SandlerBoost Price TargetOverweight$188.00 ➝ $211.00Low
10/26/2021BTIG ResearchBoost Price TargetPositive ➝ Buy$175.00 ➝ $200.00High
7/27/2021BTIG ResearchReiterated RatingBuy$165.00 ➝ $151.49Low
6/23/2021Piper SandlerBoost Price TargetOverweight$152.00 ➝ $188.00Low
6/9/2021JPMorgan Chase & Co.Initiated CoverageNeutral$146.00Low
5/24/2021BTIG ResearchInitiated CoverageBuy$165.00Low
4/30/2021BenchmarkBoost Price TargetBuy$155.00 ➝ $160.00Low
4/30/2021Piper SandlerBoost Price TargetOverweight$147.00 ➝ $152.00Medium
3/22/2021BenchmarkBoost Price TargetBuy$140.00 ➝ $155.00Low
2/2/2021Piper SandlerUpgradeNeutral ➝ Overweight$86.00 ➝ $147.00N/A
1/20/2021BenchmarkBoost Price TargetBuy$125.00 ➝ $140.00Low
1/14/2021Craig HallumBoost Price TargetBuy$100.00 ➝ $142.00Low
12/9/2020BenchmarkBoost Price TargetBuy$100.00 ➝ $125.00High
12/8/2020Berenberg BankInitiated CoverageBuyHigh
12/3/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$95.00High
10/28/2020Craig HallumBoost Price TargetBuy$85.00 ➝ $100.00High
10/28/2020Wells Fargo & CompanyBoost Price TargetEqual Weight$74.00 ➝ $84.00Low
10/28/2020BenchmarkBoost Price TargetBuy$82.00 ➝ $100.00Low
10/28/2020Cantor FitzgeraldBoost Price TargetOverweight$90.00 ➝ $95.00Low
10/28/2020Piper SandlerBoost Price TargetNeutral$70.00 ➝ $86.00Low
7/29/2020Craig HallumLower Price TargetBuy$102.00 ➝ $85.00Medium
7/29/2020Cantor FitzgeraldBoost Price TargetOverweight$85.00 ➝ $90.00High
7/29/2020Piper SandlerLower Price TargetNeutral$76.00 ➝ $70.00High
7/6/2020StephensInitiated CoverageOverweight$90.00Medium
5/8/2020BenchmarkLower Price TargetBuy$96.00 ➝ $82.00High
5/8/2020Cantor FitzgeraldLower Price TargetOverweight$95.00 ➝ $85.00High
5/8/2020Piper SandlerLower Price TargetNeutral$88.00 ➝ $76.00High
2/7/2020Piper SandlerReiterated RatingHold$88.00Medium
2/7/2020Dougherty & CoBoost Price TargetBuy$92.00 ➝ $100.00High
1/8/2020Wells Fargo & CompanyBoost Price TargetEqual Weight$80.00 ➝ $85.00Low
12/11/2019Cantor FitzgeraldReiterated RatingOverweight$91.00 ➝ $95.00Low
11/21/2019Dougherty & CoBoost Price TargetBuy$90.00 ➝ $92.00Medium
10/25/2019SidotiSet Price TargetHold$82.00N/A
7/26/2019Craig HallumUpgradeHold ➝ Buy$85.00Low
4/26/2019BenchmarkBoost Price TargetBuy$82.00 ➝ $90.00Low
4/26/2019Craig HallumDowngradeBuy ➝ Hold$84.00Low
3/7/2019Dougherty & CoBoost Price TargetBuy$78.00 ➝ $90.00Low
2/8/2019Piper Jaffray CompaniesReiterated RatingNeutral$70.00High
12/7/2018OppenheimerBoost Price TargetOutperform$86.00Low
12/6/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$70.00 ➝ $80.00Low
10/29/2018Wells Fargo & CompanyBoost Price TargetMarket Perform ➝ Market Perform$59.00 ➝ $61.00Medium
10/26/2018OppenheimerBoost Price TargetOutperform ➝ Outperform$71.00 ➝ $73.00N/A
10/26/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$63.00 ➝ $70.00High
10/5/2018BenchmarkBoost Price TargetBuy$66.00 ➝ $79.00Low
9/17/2018Craig HallumBoost Price TargetBuy$65.00 ➝ $80.00Medium
7/27/2018Piper Jaffray CompaniesBoost Price TargetNeutral ➝ Neutral$44.00 ➝ $55.00High
7/27/2018Craig HallumUpgradeHold ➝ Buy$33.00High
7/26/2018Cantor FitzgeraldReiterated RatingBuy$63.00High
6/29/2018BenchmarkInitiated CoverageBuy ➝ Buy$63.00Low
4/3/2018Cantor FitzgeraldReiterated RatingBuy$63.00Medium
2/2/2018Piper Jaffray CompaniesBoost Price TargetNeutral ➝ Neutral$38.00 ➝ $44.00High
2/2/2018Craig HallumDowngradeBuy ➝ HoldHigh
2/1/2018Cantor FitzgeraldReiterated RatingBuy$63.00High
1/29/2018OppenheimerReiterated RatingBuy$55.00Medium
12/13/2017Cantor FitzgeraldReiterated RatingBuy$60.00Medium
12/5/2017Cantor FitzgeraldReiterated RatingBuy$60.00Low
12/5/2017OppenheimerReiterated RatingBuy$55.00Low
10/30/2017Craig HallumReiterated RatingBuy$52.00 ➝ $62.00N/A
10/27/2017Cantor FitzgeraldBoost Price TargetOverweight$58.00N/A
10/19/2017OppenheimerReiterated RatingBuy$55.00N/A
9/5/2017BenchmarkBoost Price TargetBuy ➝ Buy$55.00 ➝ $67.00Medium
(Data available from 8/12/2017 forward)

News Sentiment Rating

-0.11 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 21 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/14/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/13/2022
  • 0 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/15/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/14/2022
  • 3 very positive mentions
  • 20 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
5/14/2022
  • 2 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/13/2022
  • 2 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
7/13/2022
  • 1 very positive mentions
  • 20 positive mentions
  • 7 negative mentions
  • 2 very negative mentions
Mentions as of
8/12/2022

Current Sentiment

  • 1 very positive mentions
  • 20 positive mentions
  • 7 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Omnicell logo
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
Read More

Today's Range

Now: $109.18
Low: $107.50
High: $112.88

50 Day Range

MA: $112.52
Low: $105.24
High: $124.09

52 Week Range

Now: $109.18
Low: $103.62
High: $187.29

Volume

576,094 shs

Average Volume

504,784 shs

Market Capitalization

$4.83 billion

P/E Ratio

86.65

Dividend Yield

N/A

Beta

1.04

Frequently Asked Questions

What sell-side analysts currently cover shares of Omnicell?

The following Wall Street sell-side analysts have issued stock ratings on Omnicell in the last year: BTIG Research, Craig Hallum, Piper Sandler, StockNews.com, SVB Leerink LLC, TheStreet, and Wells Fargo & Company.
View the latest analyst ratings for OMCL.

What is the current price target for Omnicell?

5 Wall Street analysts have set twelve-month price targets for Omnicell in the last year. Their average twelve-month price target is $162.40, suggesting a possible upside of 48.7%. Craig Hallum has the highest price target set, predicting OMCL will reach $205.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $124.00 for Omnicell in the next year.
View the latest price targets for OMCL.

What is the current consensus analyst rating for Omnicell?

Omnicell currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OMCL will outperform the market and that investors should add to their positions of Omnicell.
View the latest ratings for OMCL.

What other companies compete with Omnicell?

Other companies that are similar to Omnicell include Denali Therapeutics, The Ensign Group, Integra LifeSciences, Azenta and Beam Therapeutics. Learn More about companies similar to Omnicell.

How do I contact Omnicell's investor relations team?

Omnicell's physical mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company's listed phone number is (650) 251-6100 and its investor relations email address is [email protected] The official website for Omnicell is www.omnicell.com. Learn More about contacing Omnicell investor relations.